Ruan, Peifeng
Todd, Jamie L
Zhao, Hongyu
Liu, Yi
Vinisko, Richard
Soellner, Julia F.
Schmid, Ramona
Kaner, Robert J.
Luckhardt, Tracy R.
Neely, Megan L.
Noth, Imre
Porteous, Mary
Raj, Rishi
Safdar, Zeenat
Strek, Mary E
Hesslinger, Christian
Palmer, Scott M.
Leonard, Thomas B.
Salisbury, Margaret L.
Funding for this research was provided by:
The IPF-PRO/ILD-PRO Registry is funded by Boehringer Ingelheim Pharmaceuticals, Inc, and co-ordinated by the Duke Clinical Research Institute.
Article History
Received: 27 October 2022
Accepted: 26 April 2023
First Online: 31 May 2023
Declarations
:
: The IPF-PRO Registry study obtained ethics approval at the data coordinating center (Duke Clinical Research Institute, Duke Institutional Review Board Protocol Number Pro00046131) and at every enrolling center (listed in the Acknowledgments). All participants gave informed consent. Additionally, ethics approval was granted by the Duke Institutional Review Board Protocol Number Pro00082241 to use the biosamples obtained as part of the IPF-PRO Registry for the analyses contained herein.
: Not applicable.
: Peifeng Ruan, Hongyu Zhao and Mary Porteous have nothing to report. Jamie L Todd, Megan L Neely and Scott M Palmer are employees of the Duke Clinical Research Institute (DCRI) which receives funding support from Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) to coordinate the IPF-PRO/ILD-PRO Registry. Jamie L Todd also reports grants from AstraZeneca, BI, CareDx and has participated on Data Safety Monitoring Boards or Advisory Boards for Altavant Sciences, Natera, Theravance. Megan L Neely also reports honoraria for a lecture from North Carolina State University. Yi Liu, Richard Vinisko, Julia F Soellner, Ramona Schmid, Christian Hesslinger and Thomas B Leonard are employees of BI. Robert J Kaner reports grants paid to his institution from Bellerophon, BI, Genentech, the National Institutes of Health, Respivant, Toray, the US Department of Defense; royalties or licenses from UpToDate; consulting fees from AstraZeneca and Galapagos; speaker fees from BI, the France Foundation, Genentech, Vindico; has participated on Data Safety Monitoring Boards or Advisory Boards for BI, Genentech, Pliant, PureTech; holds unpaid leadership or fiduciary roles with the Pulmonary Wellness Foundation and the Stony Wold Foundation; holds stock or stock options with Air Cycle Systems and Doximity; and has received medical writing support from AstraZeneca, BI, Galapagos, Genentech. Tracy R Luckhardt reports grants from Bellerophon and FibroGen for her role as a clinical trial investigator. Imre Noth reports a contract for biospecimens from Veracyte; royalties from UpToDate; consulting fees from BI, Genentech, Sanofi; he holds a patent for a gene signature predictor of FVC and has a PCSK6 patent pending; he holds licenses for protein markers in IPF; he was a member of the Yale COVID Data Safety Monitoring Board. Rishi Raj has received an investigator-initiated research grant from BI and served on an advisory board for BI. Zeenat Safdar reports consulting fees and honoraria for lectures from BI and Genentech. Mary E Strek has served as Principal Investigator for institutional and investigator-initiated grants from BI, and for institutional grants from Galapagos, Novartis, the Pulmonary Fibrosis Foundation; received honoraria for lectures and a textbook from CHEST; served on an adjudication committee for FibroGen; is on the American Thoracic Society Clinical Problems Committee and Research Innovation Summit Planning Committee; is Chair of the PFF Registry Scientific Review Committee. Scott M Palmer reports research funding to Duke/DCRI from AstraZeneca, Bristol Myers Squibb, CareDx; royalties or licenses from UpToDate; and speaker fees from Altavant Sciences, Bristol Myers Squibb, Mereo Biopharma, Theravance. Margaret L Salisbury reports grants paid to her institution from the National Institutes of Health; consulting fees from BI, Orinove Inc., Roche; payment for lectures from BI; and reimbursement to attend an investigators’ meeting from BI.